Last week, as I do most weekday mornings at 5 am, I was flipping television channels between Bloomberg and CNBC. While watching CNBC and scanning Seeking Alpha's current news feed, I happened to watch a commercial for a product called Quell. Intrigued by both the concept and the product's purported pain management solution, I set out to learn more about it and see if the company is publicly traded.
It turns out a company by the name of NeuroMetrix, Inc. (NURO) is the manufacturer of the product. The CNBC commercial said the product was available at Best Buy (NYSE:BBY). Next, I immediately checked Amazon.com (NASDAQ:AMZN). As you can see, it's priced at $250 and there have been 163 reviews. I then scanned and read through some of the reviews, and on balance, they appeared favorable. Verified Amazon customers had confirmed that the product helps them effectively manage their pain.
